Skip to content

Long-term persistence in postmenopausal women receiving osteoporosis medications

Chronic pharmacologic treatments have the risk of low adherence and persistence which depend on the disease severity, preventive objectives, co-morbidity, other concurrent medications (polymedication) and adverse events. Wade and colleagues [1] reported follow-up data regarding osteoporosis medication persistence and switching at 24 months and 36 months in postmenopausal women from the cohort of the US… Read More

Effects of denosumab in patients with bone metastases from solid cancers

Bone antiresorptives, mostly bisphosphonates, are used in the treatment of metastatic bone disease from solid malignancies to reduce bone destruction, pain and skeleton-related events (SREs). Von Moos and colleagues [1] have reported pooled results from three randomized, identically designed, double-blind trials comparing subcutaneous denosumab (120 mg every 4 weeks) and intravenous zoledronic acid (4 mg/month)… Read More

Use of hormone therapy by Chinese ob-gyns

In a recent survey study by Wang and colleagues [1], a total of 2000 self-administered questionnaires were sent to female obstetricians-gynecologists (ob-gyns) attending the Gynecological Endocrinology workshops held from February to May 2013 in 15 provinces and cities in China. A total of 904 eligible questionnaires were collected (response rate, 45.2%). The majority of the… Read More

Fibromyalgia and menopause: any link?

The April 16 issue of [i]JAMA[/i] included a kind of a review on fibromyalgia, which was actually based on a conference that took place at the Medicine Grand Rounds at Beth Israel Deaconess Medical Center, Boston, Massachusetts, on October 2012 [1]. The article starts with a case history of a 64-year-old woman with ongoing, long-term,… Read More

International Menopause Society

Install International Menopause Society - DEV

Install this application on your home screen for quick and easy access when you’re on the go.

Just tap then “Add to Home Screen”